Discover
NPCE
NeuroPace, Inc.
15.77
2 x 11.45
1 x 15.88
bid
ask
-
0.12
0.76%
2 @ 04:00 PM
15.77 +0.00 (0.00%)
| Ytd | 2.14% | |
| 1y | 50.48% |
15.56
day range
16.29
7.56
52 week range
19.60
| Open | 15.89 | Prev Close | 15.89 | Low | 15.56 | High | 16.29 | Mkt Cap | 537.66M |
| Vol | 187.55K | Avg Vol | 183.57K | EPS | -0.65 | P/E | N/A | Forward P/E | -10.90 |
| Beta | 1.80 | Short Ratio | 2.85 | Inst. Own | 82.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 16.36 | 200-d Avg | 14.53 | 1yr Est | 16.17 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.26 | -0.19 | 0.07 | 26.92% |
| 2024-08-13 | 2024-06 | -0.29 | -0.26 | 0.03 | 10.34% |
| 2024-08-13 | 2024-06 | -0.29 | N/A | N/A | N/A |
| 2024-05-08 | 2024-03 | -0.32 | -0.32 | N/A | N/A |
| 2024-05-08 | 2024-03 | -0.32 | N/A | N/A | N/A |
| 2024-03-05 | 2023-12 | -0.33 | -0.23 | 0.1 | 30.30% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-17 | JP Morgan | Upgrade | Overweight | Overweight |
| 2024-11-13 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2024-08-14 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-08-14 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2024-07-15 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2024-05-09 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Profile
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-02-26 | BECKER JOEL | Chief Executive Officer | 52.47K | Stock Award(Grant) |
| 2023-02-20 | FAVET MICHAEL | Chief Executive Officer | 407.08K | Stock Award(Grant) |
| 2024-10-24 | KCK, LTD. | Beneficial Owner of more than 10% of a Class of Security | 5.27M | Sale |
| 2024-02-26 | KUHN REBECCA | Chief Financial Officer | 152.20K | Stock Award(Grant) |
| 2024-02-26 | MORRELL MARTHA J | Officer | 90.26K | Stock Award(Grant) |
| 2024-05-02 | ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Orbimed Advisors LLC. | 3.41M | 38.97M | 11.41% |
| 2024-09-29 | Morgan Stanley | 2.49M | 28.54M | 8.36% |
| 2024-09-29 | Soleus Capital Management, L.P. | 2.43M | 27.84M | 8.15% |
| 2024-09-29 | Kent Lake PR LLC | 1.25M | 14.30M | 4.19% |
| 2024-09-29 | Vanguard Group Inc | 995.20K | 11.39M | 3.33% |
| 2024-09-29 | Millennium Management Llc | 739.99K | 8.47M | 2.48% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 700.52K | 8.01M | 2.35% |
| 2024-10-30 | iShares Russell 2000 ETF | 289.13K | 3.31M | 0.97% |
| 2024-08-30 | Fidelity Small Cap Growth Fund | 180.77K | 2.07M | 0.61% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 161.65K | 1.85M | 0.54% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 139.42K | 1.59M | 0.47% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 116.95K | 1.34M | 0.39% |